Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 222

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 222
---
     |           |                                205 |     |             |                                    - |     |      |               - |
| Share based payment         |     |           |                                582 |     |             |                                    - |     |      |               - |
| Others                      |     |           |                                 68 |     |             |                                   62 |     |      |               7 |
|                             |     |           |                              1,153 |     |             |                                  257 |     |      |             156 |

<div align='center'>F-32</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 12 – RELATED PARTIES

As of December
31, 2024, July 23, 2024 and December 31, 2023, , the balance of trade payables totaled $26, $105, $99 and $315, respectively, is a debt
to the “Yissum” company. The “Yissum” company coordinates the economic activities for the Company’s research
services under an exclusive license agreement signed on November 24, 2022 (refer also to Note 11).

“Yissum”
owns 2.2%, 6.6%, 6.6% and 5.82% of the Company’s share capital as of December 31, 2024, July 23, 2024, December 31, 2022, and 2023,
respectively.

NOTE 13 – SEGMENT REPORTING

ASC 280,
“Segment Reporting,” establishes standards for reporting information about operating segments. Operating segments are defined
as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating
decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s business
is comprised of one operating segment.

The Company’s
CODM is its Chief Executive Officer (“CEO”), who reviews financial information presented on a consolidated basis.

The CODM
uses consolidated net loss to assess financial performance and allocate resources. These financial metrics are used by the CODM to make
key operating decisions, such as the allocation of budget between Research and development and General and Administrative expenses. Segment
assets that are reviewed by the CODM is reported within the Consolidated Balance Sheet as consolidated total assets.

The table
below summarizes the significant expense categories regularly reviewed